|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurman RJ and Ie M Shih: Pathogenesis of
ovarian cancer: Lessons from morphology and molecular biology and
their clinical implications. Int J Gynecol Pathol. 27:151–160.
2008.PubMed/NCBI
|
|
4
|
Li D, Marchenko ND and Moll UM: SAHA shows
preferential cytotoxicity in mutant p53 cancer cells by
destabilizing mutant p53 through inhibition of the HDAC6-Hsp90
chaperone axis. Cell Death Differ. 18:1904–1913. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ellis L, Hammers H and Pili R: Targeting
tumor angiogenesis with histone deacetylase inhibitors. Cancer
Lett. 280:145–153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fu S, Hou MM, Naing A, Janku F, Hess K,
Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, et al: Phase I
study of pazopanib and vorinostat: A therapeutic approach for
inhibiting mutant p53-mediated angiogenesis and facilitating mutant
p53 degradation. Ann Oncol. 26:1012–1028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matulonis U, Berlin S, Lee H, Whalen C,
Obermayer E, Penson R, Liu J, Campos S, Krasner C and Horowitz N:
Phase I study of combination of vorinostat, carboplatin, and
gemcitabine in women with recurrent, platinum-sensitive epithelial
ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother
Pharmacol. 76:417–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bast RC, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skead G and Govender D: Gene of the month:
MET. J Clin Pathol. 68:405–9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cancer Genome Atlas Research Network, .
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang J, Zhang L, Greshock J, Colligon TA,
Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al:
Frequent genetic abnormalities of the PI3K/AKT pathway in primary
ovarian cancer predict patient outcome. Genes Chromosomes Cancer.
50:606–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi KC, Auersperg N and Leung PC:
Mitogen-activated protein kinases in normal and (pre)neoplastic
ovarian surface epithelium. Reprod Biol Endocrinol. 1:712003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martins FC, Santiago ID, Trinh A, Xian J,
Guo A, Sayal K, Jimenez-Linan M, Deen S, Driver K, Mack M, et al:
Combined image and genomic analysis of high-grade serous ovarian
cancer reveals PTEN loss as a common driver event and prognostic
classifier. Genome Biol. 15:5262014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Djordjevic B, Hennessy BT, Li J, Barkoh
BA, Luthra R, Mills GB and Broaddus RR: Clinical assessment of PTEN
loss in endometrial carcinoma: Immunohistochemistry outperforms
gene sequencing. Mod Pathol. 25:699–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bakkar RM, Xie SS, Urbauer DL, Djordjevic
B, Vu K and Broaddus RR: Intact PTEN expression by
immunohistochemistry is associated with decreased survival in
advanced stage ovarian/primary peritoneal high-grade serous
carcinoma. Int J Gynecol Pathol. 34:497–506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Emmanuel C, Chiew YE, George J,
Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C,
Fereday S, Hung J, et al: Genomic classification of serous ovarian
cancer with adjacent borderline differentiates RAS pathway and
TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin
Cancer Res. 20:6618–6630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gentile A, Trusolino L and Comoglio PM:
The Met tyrosine kinase receptor in development and cancer. Cancer
Metastasis Rev. 27:85–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gherardi E, Birchmeier W, Birchmeier C and
Woude G Vande: Targeting MET in cancer: Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oza AM, Cook AD, Pfisterer J, Embleton A,
Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P,
Cervantes A, et al: Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7):
Overall survival results of a phase 3 randomised trial. Lancet
Oncol. 16:928–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aghajanian C, Goff B, Nycum LR, Wang YV,
Husain A and Blank SV: Final overall survival and safety analysis
of OCEANS, a phase 3 trial of chemotherapy with or without
bevacizumab in patients with platinum-sensitive recurrent ovarian
cancer. Gynecol Oncol. 139:10–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choueiri TK, Vaishampayan U, Rosenberg JE,
Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN,
Adams LM, et al: Phase II and biomarker study of the dual
MET/VEGFR2 inhibitor foretinib in patients with papillary renal
cell carcinoma. J Clin Oncol. 31:181–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zillhardt M, Park SM, Romero IL, Sawada K,
Montag A, Krausz T, Yamada SD, Peter ME and Lengyel E: Foretinib
(GSK1363089), an orally available multikinase inhibitor of c-Met
and VEGFR-2, blocks proliferation, induces anoikis, and impairs
ovarian cancer metastasis. Clin Cancer Res. 17:4042–4051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RH: WHO Classification of Tumours of Female Reproductive
Organs. Fourth. World Health Organization; Geneva: 2014
|
|
26
|
Meinhold-Heerlein I, Fotopoulou C, Harter
P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S and Sehouli J:
The new WHO classification of ovarian, fallopian tube, and primary
peritoneal cancer and its clinical implications. Arch Gynecol
Obstet. 293:695–700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harlé A, Filhine-Tresarrieu P, Husson M,
Boidot R, Rouyer M, Dubois C, Leroux A and Merlin JL: Rare RAS
mutations in metastatic colorectal cancer detected during routine
RAS genotyping using next generation sequencing. Target Oncol.
11:363–370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hennessy BT, Coleman RL and Markman M:
Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bonsing BA, Corver WE, Gorsira MC, van
Vliet M, Oud PS, Cornelisse CJ and Fleuren GJ: Specificity of seven
monoclonal antibodies against p53 evaluated with Western blotting,
immunohistochemistry, confocal laser scanning microscopy, and flow
cytometry. Cytometry. 28:11–24. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Psyrri A, Kountourakis P, Yu Z,
Papadimitriou C, Markakis S, Camp RL, Economopoulos T and
Dimopoulos MA: Analysis of p53 protein expression levels on ovarian
cancer tissue microarray using automated quantitative analysis
elucidates prognostic patient subsets. Ann Oncol. 18:709–715. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hashimoto T, Tokuchi Y, Hayashi M,
Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa
K, Hayashi J and Tsuchiya E: p53 null mutations undetected by
immunohistochemical staining predict a poor outcome with
early-stage non-small cell lung carcinomas. Cancer Res.
59:5572–5577. 1999.PubMed/NCBI
|
|
32
|
Köbel M, Reuss A, du Bois A, Kommoss S,
Kommoss F, Gao D, Kalloger SE, Huntsman DG and Gilks CB: The
biological and clinical value of p53 expression in pelvic
high-grade serous carcinomas. J Pathol. 222:191–198. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kmet LM, Cook LS and Magliocco AM: A
review of p53 expression and mutation in human benign, low
malignant potential, and invasive epithelial ovarian tumors.
Cancer. 97:389–404. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McEllin B, Camacho CV, Mukherjee B, Hahm
B, Tomimatsu N, Bachoo RM and Burma S: PTEN loss compromises
homologous recombination repair in astrocytes: Implications for
glioblastoma therapy with temozolomide or poly(ADP-ribose)
polymerase inhibitors. Cancer Res. 70:5457–5464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mendes-Pereira AM, Martin SA, Brough R,
McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ and Ashworth A:
Synthetic lethal targeting of PTEN mutant cells with PARP
inhibitors. EMBO Mol Med. 1:315–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang C, Jardim DLF, Falchook GS, Hess K,
Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo
Galgiato D, et al: MET nucleotide variations and amplification in
advanced ovarian cancer: Characteristics and outcomes with c-Met
inhibitors. Oncoscience. 1:5–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma PC, Kijima T, Maulik G, Fox EA, Sattler
M, Griffin JD, Johnson BE and Salgia R: c-MET mutational analysis
in small cell lung cancer: Novel juxtamembrane domain mutations
regulating cytoskeletal functions. Cancer Res. 63:6272–6281.
2003.PubMed/NCBI
|
|
38
|
Tyner JW, Fletcher LB, Wang EQ, Yang WF,
Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger
MW, Druker BJ and Loriaux MM: MET receptor sequence variants R970C
and T992I lack transforming capacity. Cancer Res. 70:6233–6277.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Arriola E, Cañadas I, Arumí-Uría M, Dómine
M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E,
Hirsch FR, et al: MET phosphorylation predicts poor outcome in
small cell lung carcinoma and its inhibition blocks HGF-induced
effects in MET mutant cell lines. Br J Cancer. 105:814–823. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Comoglio PM, Giordano S and Trusolino L:
Drug development of MET inhibitors: Targeting oncogene addiction
and expedience. Nat Rev Drug Discov. 7:504–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garrido-Castro AC, Argilés G, Moreno D,
Rodriguez-Freixinos V, Vilaro M, Macarulla T, Zambrano C Cruz,
Azaro A, Adamo B, Alsina M, et al: Molecular profiling in
gynecologic cancer and matched targeted therapy: A step toward
improving personalized medicine. J Clin Oncol 32 (Suppl 5s).
55782014.
|
|
42
|
Kinross KM, Montgomery KG, Kleinschmidt M,
Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis
T, et al: An activating Pik3ca mutation coupled with Pten loss is
sufficient to initiate ovarian tumorigenesis in mice. J Clin
Invest. 122:553–557. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol.
30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fritsch C, Huang A, Chatenay-Rivauday C,
Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De
Pover A, et al: Characterization of the novel and specific PI3Kα
inhibitor NVP-BYL719 and development of the patient stratification
strategy for clinical trials. Mol Cancer Ther. 13:1117–1129. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ascierto PA, Schadendorf D, Berking C,
Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck
JT, St-Pierre A, et al: MEK162 for patients with advanced melanoma
harbouring NRAS or Val600 BRAF mutations: A non-randomised,
open-label phase 2 study. Lancet Oncol. 14:249–256. 2013.
View Article : Google Scholar : PubMed/NCBI
|
